Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 adjunctive MK-1167 in mild to moderate Alzheimer's disease dementia
2024-515539-31-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing MK-1167 arm with Placebo arm (2 arms). Primary endpoints: Change From Baseline in ADAS-Cog11 Total Score at Week 24, Number of participants with one or more adverse events and 1 more. Started Mar 2025; status: completed.
02
Drugs
MK-1167
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-515539-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515539-31-00.